AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT02097745

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

A Phase 3 study testing methotrexate and rituximab [MabThera/Rituxan] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 97 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
methotrexate and rituximab [MabThera/Rituxan]
Could I receive a placebo?
No, everyone receives an active treatment
How many people
341 participants
Where
97 sitesin 11 countries
Study dates
Jun 2004to Jun 2013
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • adult patients 18-80 years of age with active RA;
  • patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;
  • eligible for re-treatment, based on clinical symptoms;
  • patients of reproductive potential must be using reliable contraceptive methods.

Who cannot join

  • patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;
  • current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;
  • development of any new contraindications to receiving MabThera;
  • women who are pregnant or breast-feeding.

Trial locations and contacts

97 sites in 11 countries.

97 sites in 11 countries

United States59 sites
  • Study site

    Albany, New York, 12206

  • Study site

    Amarillo, Texas, 79124

  • Study site

    Baltimore, Maryland, 21224

  • Study site

    Boca Raton, Florida, 33486

  • Study site

    Boise, Idaho, 83702

  • Study site

    Boston, Massachusetts, 02215

  • Study site

    Burlington, Vermont, 05401

  • Study site

    Chapel Hill, North Carolina, 27599-7600

  • Study site

    Chicago, Illinois, 60612

  • Study site

    Chicago, Illinois, 60637

  • Study site

    Cincinnati, Ohio, 45267-0563

  • Study site

    Coeur d'Alene, Idaho, 83814

  • Study site

    Dallas, Texas, 75231

  • Study site

    Dallas, Texas, 75246

  • Study site

    Danbury, Connecticut, 06810

  • Study site

    Dayton, Ohio, 45402

  • Study site

    Delray Beach, Florida, 33484

  • Study site

    Duncansville, Pennsylvania, 16635

  • Study site

    Fort Lauderdale, Florida, 33334

  • Study site

    Fullerton, California, 92835

  • Study site

    Greenville, North Carolina, 27834

  • Study site

    Houston, Texas, 77074

  • Study site

    Indianapolis, Indiana, 46202-5149

  • Study site

    Indianapolis, Indiana, 46260

  • Study site

    Jupiter, Florida, 33458

  • Study site

    Kalamazoo, Michigan, 49048

  • Study site

    Lansing, Michigan, 48910

  • Study site

    Little Rock, Arkansas, 72205

  • Study site

    Los Angeles, California, 90045

  • Study site

    Los Angeles, California, 90048

  • Study site

    Madison, Wisconsin, 53792

  • Study site

    Manhasset, New York, 11030

  • Study site

    Mayfield, Ohio, 44143

  • Study site

    Meridian, Idaho, 83642

  • Study site

    Mesa, Arizona, 85208

  • Study site

    New York, New York, 10003

  • Study site

    Oklahoma City, Oklahoma, 73103

  • Study site

    Oklahoma City, Oklahoma, 73109

  • Study site

    Orlando, Florida, 32806

  • Study site

    Paradise Valley, Arizona, 85253

  • Study site

    Pasadena, California, 91105

  • Study site

    Philadelphia, Pennsylvania, 19140

  • Study site

    Philadelphia, Pennsylvania, 19141

  • Study site

    Philadelphia, Pennsylvania, 19152

  • Study site

    Rancho Mirage, California, 92270

  • Study site

    Rochester, Minnesota, 55905

  • Study site

    Rochester, New York, 14618

  • Study site

    Salt Lake City, Utah, 84132

  • Study site

    Santa Maria, California, 93454

  • Study site

    Seattle, Washington, 98101

  • Study site

    Seattle, Washington, 98104

  • Study site

    Shreverport, Louisiana, 71103

  • Study site

    Smithtown, New York, 11787

  • Study site

    Spokane, Washington, 99204

  • Study site

    St Louis, Missouri, 63110

  • Study site

    St Louis, Missouri, 63141

  • Study site

    Tucson, Arizona, 85724

  • Study site

    Tulsa, Oklahoma, 74135

  • Study site

    Waco, Texas, 76710

Other trials in United States

Israel6 sites
  • Study site

    Haifa, 3109601

  • Study site

    Haifa, 3339419

  • Study site

    Jerusalem, 9112001

  • Study site

    Petah Tikva, 4941492

  • Study site

    Ramat Gan, 5262000

  • Study site

    Tel Aviv, 6423906

Other trials in Israel

Canada5 sites
  • Study site

    Calgary, Alberta, T2N 4Z6

  • Study site

    Edmonton, Alberta, T6G 2S2

  • Study site

    Hamilton, Ontario, L8N 2B6

  • Study site

    London, Ontario, N6A 4V2

  • Study site

    Toronto, Ontario, M4N 3M5

Other trials in Canada

France5 sites
  • Study site

    Bois-Guillaume, 76233

  • Study site

    Le Kremlin-Bicêtre, 94275

  • Study site

    Montpellier, 34295

  • Study site

    Paris, 75679

  • Study site

    Toulouse, 31059

Other trials in France

Germany5 sites
  • Study site

    Berlin, 10117

  • Study site

    Dresden, 01067

  • Study site

    Leipzig, 04103

  • Study site

    Ratingen, 40882

  • Study site

    Würzburg, 97080

Other trials in Germany

United Kingdom5 sites
  • Study site

    Cannock, WS11 5XY

  • Study site

    Leeds, LS7 4SA

  • Study site

    London, E11 1NR

  • Study site

    Manchester, M41 5SL

  • Study site

    Newcastle upon Tyne, NE1 4LP

Other trials in United Kingdom

Belgium3 sites
  • Study site

    Brussels, 1070

  • Study site

    Brussels, 1200

  • Study site

    Ghent, 9000

Other trials in Belgium

Italy3 sites
  • Study site

    Brescia, Lombardy, 25123

  • Study site

    Pisa, Tuscany, 56100

  • Study site

    Udine, Friuli Venezia Giulia, 33100

Other trials in Italy

Norway3 sites
  • Study site

    Drammen, 3004

  • Study site

    Oslo, 0370

  • Study site

    Tromsø, 9038

Other trials in Norway

Ireland2 sites
  • Study site

    Cork

  • Study site

    Dublin, 4

Other trials in Ireland

Netherlands1 site
  • Study site

    Amsterdam, 1105 AZ

Other trials in Netherlands

About this study

Official title: An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies

This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.

Being tested
methotrexate, rituximab [MabThera/Rituxan]
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • methotrexateDrug

    a 10-25 mg stable dose given orally or parenterally throughout study

  • rituximab [MabThera/Rituxan]Drug

    Also called MabThera/Rituxan

    1 g given by intravenous infusion on Days 1 and 15 of each treatment course

Study groups in NCT02097745
Study groupRoleWhat they receive
MabThera/RituxanExperimentalNot described
Receives: Drug: methotrexate; Drug: rituximab [MabThera/Rituxan]

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response

    A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from Baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity [symptom-free and no arthritis symptoms], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). The ACR20 response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

Secondary outcomes (12)
  1. Change From Baseline in the Disease Activity Score 28 (DAS28)

    The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score represents higher disease activity. A negative change score indicates improvement. The first retreatment may have occurred in the precursor study WA17042.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  2. Percentage of Participants With DAS28 Low Disease Activity and DAS28 Remission

    The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Low disease activity was defined as a DAS28 score ≤ 3.2. DAS28 remission was defined as a DAS28 score < 2.6. The first retreatment may have occurred in the precursor study WA17042.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  3. Percentage of Participants With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses

    Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of < -1.2 was a good response, < -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score > 3.2 to ≤ 5.1, a change from baseline of < -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score > 5.1, a change from baseline < -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores > 3.2. The first retreatment may have occurred in the precursor study WA17042.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  4. Change From Baseline in the American College of Rheumatology n (ACRn) Response

    The ACRn response was defined as each participant's least favorable percentage change from Baseline in 3 measures, tender joint count, swollen joint count (28 assessed joints), and improvement score achieved in at least 3 of the 5 remaining ACR parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity, right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain, right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate). A higher change percentage indicates greater improvement from Baseline. The ACRn response was compared to Baseline in the precursor study WA17042. The first retreatment may have occurred in the precursor study WA17042.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  5. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  6. Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey

    The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  7. Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score

    The FACIT-F is a 13-item participant self-reporting questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.

    Measured: Baseline to the end of the retreatment period (up to 7 years, 6 months)

  8. Percentage of Participants With no Radiographic Progression From Baseline to Year 5

    Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. Data is reported for 2 groups.

    Measured: Baseline to Year 5

  9. Change From Baseline in the Total Genant-modified Sharp Score at Year 5

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

    Measured: Baseline to Year 5

  10. Change From Baseline in the Genant-modified Sharp Erosion Score at Year 5

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140 which is normalized to 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

    Measured: Baseline to Year 5

  11. Change From Baseline in the Genant-modified Sharp Joint Space Narrowing Score at Year 5

    The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score joint space narrowing of 0-4 (9 gradations) is assigned to 13 joints in each hand and 6 joints in each foot. The maximum joint space narrowing score is 38 x 4.0 = 152 which is normalized to a score of 145. The minimum score is 0 and the maximum score is 145. A higher score indicates more damage. A negative change score indicates improvement. Data is reported for 2 groups.

    Measured: Baseline to Year 5

  12. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Year 5

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Participants completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement. Data is reported for 2 groups.

    Measured: Baseline to Year 5

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2014 (estimated)
  2. Study startJun 2004
  3. Primary completionJun 2013
  4. Study completionJun 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
341 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02097745
Sponsor's protocol ID
WA17531
Status last verified
Sep 2016
First submitted
20 Mar 2014
Last updated
3 Nov 2016

Publications

  • Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007 Dec;56(12):3896-908. doi: 10.1002/art.23059.

    PubMed 18050221

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing methotrexate and rituximab [MabThera/Rituxan] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 97 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 97 sites in United States, Israel, Canada, France, Germany and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 Nov 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response (time frame: Baseline to the end of the retreatment period (up to 7 years, 6 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02097745, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in